Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Chugai to Absorb Renalys Pharma in Late December
Chugai Pharmaceutical said on November 18 that it will merge Renalys Pharma into the company on December 29, following its planned acquisition of the biotech, which owns the IgA nephropathy drug sparsentan in Japan and several other Asian markets. In…
To read the full story
Related Article
- Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track
November 27, 2025
- Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
- Renalys Raises 6 Billion Yen in Series A Financing to Push IgA Med
July 18, 2024
- Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…